Low-dose Buprenorphine/Naloxone Initiation for Chronic Non-cancer Pain

Clinical Bottom Line

Traditional buprenorphine induction requires patients to be in moderate opioid withdrawal before starting treatment—a significant barrier for patients on long-term, high-dose opioid therapy. This study demonstrates that low-dose initiation (microdosing) offers a gentler alternative with high success rates.

Key Findings

1. High Success Rate: 94.4% of patients (17 of 18) successfully completed the transition to buprenorphine/naloxone maintenance therapy.
2. Flexible Protocol: The low-dose approach was individualized based on patient response, allowing for adjustments without precipitating severe withdrawal.
3. Manageable Side Effects: While adverse effects such as nausea were common during the transition, they typically resolved once stable maintenance doses were achieved.
4. No Withdrawal Crisis: Unlike traditional induction, patients did not need to endure moderate withdrawal symptoms before starting buprenorphine.

Clinical Takeaway

"Microdosing buprenorphine offers a patient-centered approach to transitioning individuals with chronic non-cancer pain off high-dose opioids. By avoiding the withdrawal requirement of traditional induction, this method may improve patient acceptance and completion rates for buprenorphine therapy."